Network metaanalysis and cost per responder of tumor necrosis factor, interleukin, and phosphodiesterase inhibitors in the treatment of psoriatic arthritis

被引：0
|
作者：
Strand, Vibeke [1 ]
Husni, M. Elaine [2 ]
Griffith, Jenny [3 ]
Betts, Keith [4 ]
Beppu, Marci [3 ]
Song, Yan [4 ]
Ganguli, Arijit [3 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
2534
引用
收藏
页码：AB260 / AB260
页数：1
相关论文
共 50 条
  • [21] Tumor necrosis factor inhibitors continuationrates in patients with psoriatic arthritis: A Frenchretrospective monocentre study
    Rio, Simon
    Vincent, Fabien B.
    Michel, Murielle
    Cesini, Johann
    Marcelli, Christian
    JOINT BONE SPINE, 2015, 82 (05) : 377 - 378
  • [22] The Effects of Tumor Necrosis Factor Inhibitors in a Particular Association of Psoriatic Arthritis and Behcet Disease
    Musetescu, Anca Emanuela
    Florescu, Alesandra
    Bumbea, Ana-Maria
    Florescu, Lucian Mihai
    Ciurea, Paulina Lucia
    Bondari, Andrei
    Florescu, Dan Nicolae
    Bondari, Simona
    REVISTA DE CHIMIE, 2019, 70 (03): : 1067 - 1070
  • [23] Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US
    Strand V.
    Husni E.
    Griffith J.
    Zhou Z.-Y.
    Signorovitch J.
    Ganguli A.
    Rheumatology and Therapy, 2016, 3 (2) : 305 - 322
  • [24] Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study
    Ogdie, Alexis
    Shaw, Yomei
    Almonte, Michele
    Maksabedian, Hernande Ervant J.
    Stolshek, Bradley
    Michaud, Kaleb
    ACR OPEN RHEUMATOLOGY, 2023, 5 (04) : 167 - 172
  • [25] COST PER RESPONDER OF APREMILAST VERSUS ETANERCEPT AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Tencer, T.
    Clancy, Z.
    Zhang, F.
    VALUE IN HEALTH, 2014, 17 (07) : A376 - A376
  • [26] A cost-efficacy analysis of subcutaneous anti-tumor necrosis factor therapy in the treatment of psoriatic arthritis
    Tandon, N.
    Kavanaugh, A.
    Han, C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB6 - AB6
  • [27] COST PER-RESPONDER ANALYSIS OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN SAUDI ARABIA
    Al Hamdan, H.
    Al Howimel, M.
    Al Jufan, K.
    Al Mudaiheem, H.
    AlAlwan, A.
    Alshehri, N.
    Zakaria, N.
    Al Kateb, L.
    Ramakrishna, G.
    VALUE IN HEALTH, 2018, 21 : S82 - S82
  • [28] Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    George, Michael D.
    Baker, Joshua F.
    Ogdie, Alexis
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (06) : 826 - 834
  • [29] Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis
    Fantuzzi, Francesca
    Del Giglio, Micol
    Gisondi, Paolo
    Girolomoni, Giampiero
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (09) : 1085 - 1096
  • [30] Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab
    Cauza, E
    Spak, M
    Cauza, K
    Hanusch-Enserer, U
    Dunky, A
    Wagner, E
    RHEUMATOLOGY INTERNATIONAL, 2002, 22 (06) : 227 - 232
12345